Data from a validation study of NRG-RTOG 0521 suggeststhat, while there is no association between an elevated level of C-reactive protein (CRP) and disease-free survival (DFS); higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of DFS. These results were recently presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
The initial study, NRG-RTOG 0521 (Hall 2013), indicated that elevated CRP levels, a marker of inflammation, were directly associated with shorter biochemical failurefreesurvival after radiotherapy for patients with high risk prostate cancer. During this study, serum samples were collected from 202 participants and banked for futurebiomarker validation. Researchers measured multiple serum immuno-inflammatory cytokines in addition to CRP levels. The primary objective for the validation studywas to determine the association between CRP levels and DFS from time of patient randomization and additional objectives included the correlation of cytokine levelswith DFS and toxicity events due to radiotherapy.
"Although CRP levels did not correlate with DFS, the association of higher baseline levels of IL-10 with poorer outcome supports the claim that there may be an interaction between host pretreatment immune inflammatory state and the outcomes for the patient following radiotherapy treatment. I believe that future investigation into anti-inflammatory medical intervention for patients with prostate cancer in association to radiotherapy would be worthwhile," stated William A. Hall, MD, an Assistant Professor of Radiation Oncology at the Medical College of Wisconsin and lead author of this abstract.
Serum immune-inflammatory cytokines that were studied included: monocyte chemotactic protein-1 (MCP-1),granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon gamma (IFN-γ), IL-1b, IL-2, IL-4, IL5,IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, IL-23, and tumor necrosis factor (TNFα). In addition to the association between IL-10 and DFS, IL-12 and IL-13 were also associated with grade 2 or higher cystitis, or inflammation of the bladder.
More information: Hall WA, Karrison T, Rosenthal SA, Amin M, Gomella LG, Purdy J, Sartor AO, Michalski J, Garzotto M, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore J, Gore E, Lee WR, Nguyen PL, Danielson B, Sandler HM, Feng FY. The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521. Abstract presented at the annual meeting of the American Society for Radiation Oncology (ASTRO). San Antonio, TX.
Provided by NRG Oncology
